Otrivin Baby Nasal Drops
Otrivin Paed Nasal Drops are shown to provide quick and effective relief from nasal congestion in babies.
A formulation designed to be used in infants not less than 2 years of age, Otrivin Paed nasal drops acts fast to relieve nasal congestion and restore nasal breathing of congestion from colds.1
The decongestive effects acts fast to relieve nasal congestion and restore nasal breathing with a single application,1 resulting in:
- Improved nasal airflow1,2
- Reduced mucus production
Increased drainage of blocked secretions1
Otrivin Paed is formulated as nasal drops to bring targeted relief from nasal decongestion. The active ingredient of xylometazoline acts locally on the nasal mucosa1,2 to effect vasoconstriction where it counts, resulting in faster and longer-lasting relief than oral decongestants.2
Otrivin Paed nasal drops (0,5 mg/ml of xylometazoline hydrochloride)
For parents who are looking for a well- tolerated, effective method of clearing their baby’s nose of congestion.
1 ml contains 0,5 mg of xylometazoline hydrochloride. Preservative: 0,011 % m/v benzalkonium chloride.
Excipients: disodium edetate, disodium phosphate dodecahydrate, methylhydroxypropyl-cellulose, purified water, sodium chloride, sodium dihydrogen phosphate dihydrate, sorbitol 70 % (non-crystallising).
OTRIVIN PAED NASAL DROPS (0,5 mg/ml) are for nasal administration only, for children aged 2 up to 12 years of age: 1 to 2 drops of the 0, 5 mg/ml solution or one puff of the metered-dose spray into each nostril, once or twice daily, are generally sufficient; a total of 2 applications a day should not be exceeded3.
OTRIVIN should be used after blowing the nose3.
NOTE: In children aged 2 up to 12 years of age, only OTRIVIN PAED NASAL DROPS of 0, 5 mg/ml should be employed3.
ALWAYS READ THE LABEL BEFORE USE3.
WARNINGS AND SPECIAL PRECAUTIONS:
OTRIVIN should be used with caution in patients showing a strong reaction to sympathomimetic agents, as evidenced by signs of insomnia, dizziness as manifested by signs of insomnia, dizziness, tremor, cardiac dysrhythmias or elevated blood pressure.
OTRIVIN should be used with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, epistaxis, pheochromocytoma, prostatic hypertrophy, monoamine oxidase inhibitors (MAOI) treatment or who have received them in the last two weeks (see INTERACTIONS).
Do not exceed the recommended dose, especially in children and in the elderly.
OTRIVIN should not be used for more than ten consecutive days: prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa.
The concomitant use of OTRIVIN with monoamine oxidase (MAO) inhibitors or tricyclic or tetracyclic antidepressants may cause an increase in blood pressure due to cardiovascular effects of these substances (see WARNINGS AND SPECIAL PRECAUTIONS).